Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Catabasis to present data from extension phase of DMD med edasalonexent in early October; shares up 8%

Published 09/14/2017, 10:08 AM
© Reuters.  Catabasis to present data from extension phase of DMD med edasalonexent in early October; shares up 8%
ATXS
-
  • Thinly traded nano cap Catabasis Pharmaceuticals (CATB +7.6%) adds to its recent up move on a healthy 6x surge in volume. Shares have rallied 28% since August 24.
  • The company will present 24- and 36-week data on edasalonexent in boys with Duchenne muscular dystrophy at the 22nd International Congress of the World Muscle Society in France on Wednesday, October 4.
  • Edasalonexent, a small molecule inhibitor of a protein called NF-kB, has Orphan Drug, Fast Track and Rare Pediatric Disease status in the U.S. and Orphan Drug status in Europe.
  • Now read: Catabasis Pharmaceuticals (CATB) Presents At Wedbush PacGrow Healthcare Conference - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.